(This show was recorded on 31st July 2025)
Brian and Mik catch up on a few investment ideas they have been following
What we cover
- ANSYS × Synopsys: the deal closed; why a stock-and-cash structure gave us yield and long-term exposure, and how we’re thinking about integration risk and the opportunity ahead. (TLdR: We are still long Synosys)
- Semis & the “foundry question”: Intel sentiment whiplash, a new CEO with a turnaround pedigree, and the reality of competing with TSMC scale. We speculate on Intel's potential outcome(s) and what second-order effects may be for the ecosystem, including TSMC.
- Viking Therapeutics (VKTX): why a fast-follower with both subcutaneous and oral programs still looks interesting in a market dominated by Novo/Lilly; the real risks (short interest, dilution, timelines) and why patience, position sizing and buying well matters.
- Process over predictions: how we use updates like these to revisit assumptions without over-trading the noise.
Disclaimer: The views expressed are for entertainment purposes only. This is not investment advice. Please do your own research before making any financial decisions.
